Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.37 USD | -1.79% | -2.42% | -10.92% |
05-10 | Exelixis Files Patent Complaint Against Cipla's Cancer Treatment | DJ |
05-01 | RBC Trims Exelixis' Price Target to $27 From $28, Outperform Rating Kept | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.92% | 6.22B | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- EXEL Stock
- News Exelixis, Inc.
- Wells Fargo Starts Exelixis at Overweight With $23 Price Target